ATS 2022 TRAVERSE Trial of Dupilumab for Severe Oral Corticosteroid-Dependent Asthma Publish Date May 19, 2022 TRAVERSE trial findings on the efficacy, safety, and OCS-sparring effect of dupilumab for severe OCS-dependent asthma were presented at ATS 2022.
